Related Experiment Video

Updated: Mar 2, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.2K

Do Omega-3 Fatty Acids Decrease the Incidence of Atrial Fibrillation?

Peter Ofman1,2,3, Adelqui Peralta1, Peter Hoffmeister1

  • 1Division of Cardiology, VA Boston Healthcare System and Harvard Medical School, Boston, MA.

Journal of Atrial Fibrillation
|May 13, 2017
PubMed

Insights

Omega-3 fatty acids may prevent atrial fibrillation by altering heart tissue physiology. This review examines their use for preventing atrial fibrillation in various patient groups.

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • Atrial fibrillation (AF) is a prevalent condition, particularly after open-heart surgery.
  • Limited therapeutic options exist for AF prevention and management.
  • N-3 polyunsaturated fatty acids (PUFAs) show potential in mitigating AF susceptibility.

Purpose of the Study:

  • To review the physiological mechanisms by which n-3 PUFAs may prevent AF.
  • To evaluate the efficacy of n-3 PUFAs in primary and secondary AF prevention.
  • To assess n-3 PUFA use across general, surgical, and specific patient populations.

Main Methods:

  • Literature review of physiological studies.
  • Analysis of observational studies on n-3 PUFA use for AF.
  • Evaluation of interventional trials investigating n-3 PUFAs for AF prevention.

Main Results:

  • N-3 PUFAs modify atrial tissue electrophysiology, reducing AF inducibility.
  • Evidence suggests n-3 PUFAs are beneficial for AF prevention in diverse patient cohorts.
  • Studies indicate efficacy in both primary and secondary AF prevention strategies.

Conclusions:

  • N-3 PUFAs represent a promising therapeutic strategy for atrial fibrillation.
  • Further research supports the role of n-3 PUFAs in managing AF.
  • Targeted application of n-3 PUFAs can improve AF prevention outcomes.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.6K
Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice08:05

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice

Published on: June 29, 2022

3.6K

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
523
Structure of Lipids03:38

Structure of Lipids

Lipids include a diverse group of compounds that are largely nonpolar in nature. This is because they are hydrocarbons that include mostly nonpolar carbon-carbon or carbon-hydrogen bonds. Non-polar molecules are hydrophobic (“water fearing”), or insoluble in water. Lipids perform many different functions in a cell. Cells store energy for long-term use in the form of fats. Lipids also provide insulation from the environment for plants and animals. For example, they help keep aquatic...
100.1K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
776
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
342
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
423
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.7K